Edurant 25 mg FC TABLETS
PDF Leaflet Revision Date: 19 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in treatment-nau00efve adults and adolescents (12-17 years).
Dosage (summary)
25 mg once daily with a meal; increase to 50 mg with rifabutin.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Monitor viral load closely during pregnancy; not recommended for breastfeeding.
Key Drug Interactions
- CYP3A inducers (e.g., rifampicin)
- Proton pump inhibitors
- NNRTIs
Contraindications
- Hypersensitivity to rilpivirine
- Co-administration with certain anticonvulsants
Common side effects
- Depression
- Insomnia
- Headache
- Rash
- Nausea
- Dizziness
Counselling Points
- Take with food
- Do not skip doses
- Use additional precautions to prevent HIV transmission
Serious warnings
- Risk of virologic failure with high baseline viral load
- Immune reconstitution inflammatory syndrome
Important Disclaimer
The Edurant 25 mg FC TABLETS professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
